Long-term symptom management involves maintaining normal activity and reducing risk of future exacerbations - read more
Welcome to the Symptomatic Asthma Learning Zone
This educational resource is for European healthcare professionals involved in the care of patients with asthma. SPIRIVA® Respimat® is approved for use in asthma in the European Union, Japan, USA and many other countries (Boehringer Ingelheim, 2015). The indication varies by country and this educational resource may contain information about medications for which indications may not be approved in your country.